Elisabeth Boucher
Director, Analytical Development Tessera Therapeutics
Seminars
Wednesday 25th February 2026
Roundtable Discussion: Translating Complex mRNA Characterization Assays into QC-Ready Strategies to Reduce Downtime between Teams
9:30 am
- How to adapt AD assays into validated QC workflows to ensure reproducibility across sites and manufacturing scales
- How to overcome challenges of assay transfer, variability, and lack of reference standards to safeguard consistency and compliance
- How to embed standardized characterization workflows to support smoother regulatory submissions, tech transfer and global comparability
Wednesday 25th February 2026
Advancing Impurity and Residual Analysis to Strengthen mRNA Product Quality & QC Readiness
3:10 pm
- Developing and optimizing assays to detect and quantify critical impurities and residuals including dsRNA, proteins, and DNA in mRNA therapeutics
- Translating analytical rigor from development to QC to ensure reproducibility, compliance, and regulatory acceptance
